vs
Side-by-side financial comparison of JBG SMITH Properties (JBGS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $127.6M, roughly 1.0× JBG SMITH Properties). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -2.5%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -6.3%).
JBG SMITH PropertiesJBGSEarnings & Financial Report
JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
JBGS vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $127.6M | $129.7M |
| Net Profit | $-45.5M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | -47.5% | -25.0% |
| Net Margin | -35.7% | — |
| Revenue YoY | -2.5% | 73.4% |
| Net Profit YoY | 24.0% | — |
| EPS (diluted) | $-0.76 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $127.6M | $129.7M | ||
| Q3 25 | $123.9M | $164.9M | ||
| Q2 25 | $126.5M | $114.4M | ||
| Q1 25 | $120.7M | $81.7M | ||
| Q4 24 | $130.8M | $74.8M | ||
| Q3 24 | $136.0M | $62.9M | ||
| Q2 24 | $135.3M | $54.1M | ||
| Q1 24 | $145.2M | $41.4M |
| Q4 25 | $-45.5M | — | ||
| Q3 25 | $-28.6M | $25.7M | ||
| Q2 25 | $-19.2M | $-12.8M | ||
| Q1 25 | $-45.7M | $-41.2M | ||
| Q4 24 | $-59.9M | — | ||
| Q3 24 | $-27.0M | $-54.8M | ||
| Q2 24 | $-24.4M | $-70.4M | ||
| Q1 24 | $-32.3M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | -47.5% | -25.0% | ||
| Q3 25 | -27.5% | 15.1% | ||
| Q2 25 | -18.4% | -11.1% | ||
| Q1 25 | -44.7% | -52.2% | ||
| Q4 24 | -53.6% | -81.2% | ||
| Q3 24 | -22.4% | -89.3% | ||
| Q2 24 | -24.3% | -125.1% | ||
| Q1 24 | -30.1% | -336.5% |
| Q4 25 | -35.7% | — | ||
| Q3 25 | -23.1% | 15.6% | ||
| Q2 25 | -15.2% | -11.1% | ||
| Q1 25 | -37.9% | -50.4% | ||
| Q4 24 | -45.8% | — | ||
| Q3 24 | -19.8% | -87.1% | ||
| Q2 24 | -18.0% | -130.1% | ||
| Q1 24 | -22.2% | -328.9% |
| Q4 25 | $-0.76 | $0.04 | ||
| Q3 25 | $-0.48 | $0.28 | ||
| Q2 25 | $-0.29 | $-0.14 | ||
| Q1 25 | $-0.56 | $-0.47 | ||
| Q4 24 | $-0.70 | $-0.71 | ||
| Q3 24 | $-0.32 | $-0.70 | ||
| Q2 24 | $-0.27 | $-0.91 | ||
| Q1 24 | $-0.36 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $75.3M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $114.8M |
| Total Assets | $4.4B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.3M | $93.0M | ||
| Q3 25 | $64.4M | $110.9M | ||
| Q2 25 | $61.4M | $75.2M | ||
| Q1 25 | $81.3M | $61.9M | ||
| Q4 24 | $145.8M | $58.5M | ||
| Q3 24 | $137.0M | $36.4M | ||
| Q2 24 | $163.5M | $32.3M | ||
| Q1 24 | $220.5M | $43.3M |
| Q4 25 | $1.2B | $114.8M | ||
| Q3 25 | $1.2B | $73.6M | ||
| Q2 25 | $1.3B | $32.7M | ||
| Q1 25 | $1.6B | $32.8M | ||
| Q4 24 | $1.8B | $59.1M | ||
| Q3 24 | $1.9B | $-30.5M | ||
| Q2 24 | $2.0B | $15.1M | ||
| Q1 24 | $2.1B | $74.1M |
| Q4 25 | $4.4B | $605.2M | ||
| Q3 25 | $4.4B | $538.6M | ||
| Q2 25 | $4.5B | $555.3M | ||
| Q1 25 | $4.7B | $548.8M | ||
| Q4 24 | $5.0B | $594.1M | ||
| Q3 24 | $5.2B | $504.4M | ||
| Q2 24 | $5.3B | $551.1M | ||
| Q1 24 | $5.4B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.3M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.3M | $60.7M | ||
| Q3 25 | $8.9M | $14.3M | ||
| Q2 25 | $18.8M | $5.0M | ||
| Q1 25 | $12.9M | $-42.2M | ||
| Q4 24 | $129.4M | $-35.7M | ||
| Q3 24 | $26.4M | $-42.5M | ||
| Q2 24 | $23.8M | $-40.2M | ||
| Q1 24 | $37.0M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JBGS
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
